Original Article

Cytoskeleton-linking membrane protein 63 as a serum biomarker for the early detection of hepatocellular carcinoma

Shuangxi Li1,2,*, Hui Wang1,*, Jianling Fan3, Changzheng Wang1,4, Liwei Dong4, Zhengrong Zhong5,6, Ning Yang1

1Department of Liver Medicine, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P. R. China; 2Department of Nephrology, Changhai Hospital, Second Military Medical University, Shanghai, P. R. China; 3Department of Hematology, The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, Shanghai, P. R. China; 4International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, The Second Military Medical University, Shanghai, P. R. China; 5Department of The Clinical Laboratory, The First Affiliated Hospital of Bengbu Medical College, Anhui, P. R. China; 6Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, P. R. China. *Equal contributors.

Received November 11, 2015; Accepted January 12, 2016; Epub February 1, 2016; Published February 15, 2016

Abstract: The serum alpha-fetoprotein (AFP) is a common marker for diagnosis of hepatocellular carcinoma (HCC). But the disadvantage like low specificity and sensitivity of AFP detection in the diagnosis of HCC are problems in clinical practice. The aim of this study was to investigate the clinical value of serum cytoskeleton-linking membrane protein (CLIMP)-63 in the diagnosis of HCC. Liver and serum samples from DEN-induced hepatocarcinogenesis in Rats were used to detect CLIMP-63 level. Serum samples were collected from 40 healthy volunteers and 90 patients with HCC confirmed by pathology. The patients were divided into subgroups according to the baseline AFP level as follows: ≤5, ≤10, ≤20 ng/ml. The serum CLIMP-63 was determined with enzyme-linked immunosorbent asays (ELISAs). The area under the receiver operating characteristic curve (AuROC), sensitivity and specificity of AFP and CLIMP-63 levels were evaluated for diagnostic performance with positive biopsy. The liver CLIMP-63 levels tend to increase according to the progression of DEN-treatment rats. The serum CLIMP-63 level after DEN-injection 10 weeks was remarkably higher than it from the non DEN-treatment rats. The serum CLIMP-63 levels in HCC patients were much higher than that in healthy volunteers (P<0.05). Furthermore, the AuROC for serum CLIMP-63 in the diagnosis of HCC was 0.771 (P=0.000), and for serum AFP was 0.892 (P=0.000). In the subgroups, the AuROC of AFP level of ≤5, ≤10, ≤20 ng /ml in the diagnosis HCC was 0.629 (P=0.110), 0.652 (P=0.034), 0.705 (P=0.003) respectively. While the AuROC of serum CLIMP-63 was 0.777 (P=0.001), 0.769 (P=0.000), 0.759 (P=0.000) respectively. CLIMP-63 may be a novel serum biomarker for clinical diagnosis of HCC in the early stage and testing serum CLIMP-63 and AFP may improve the detection rate of HCC.

Keywords: Cytoskeleton-linking membrane protein (CLIMP)-63, alpha-fetoprotein (AFP), hepatocellular carcinoma (HCC), diagnosis

Introduction

Hepatocellular carcinoma (HCC) has become the most common solid tumor worldwide and the third leading cause of tumor-related death in many countries [1]. An estimated 748,300 new liver cancer cases and 695,900 cancer deaths occurred worldwide in 2008. Half of these cases and deaths was estimated to occur in China [2]. The prognosis of patients with HCC is generally very poor with a 5-year survival rate of less than 10-15% owing to lack of effective and timely diagnostic methods [3]. Therefore, early diagnosis is extremely important for improving clinical outcomes. Currently, a-fetoprotein (AFP) is the most important tumor mark for HCC diagnosis. However, AFP level is insensitive for the detection of HCC at the commonly used cutoff of 20 ng/ml. Furthermore, the specificity of AFP is low due to many patients with hepatitis, hepatocirrhosis and gastrointestinal cancer also have elevated serum levels of
CLIMP-63 as a serum biomarker for HCC

AFP [4]. Therefore, novel serum makers to complement AFP are needed to improve the diagnostic accuracy of HCC.

Cytoskeleton-linking membrane protein (CLIMP)-63 is a type II transmembrane protein that is located in the endoplasmic reticulum [5, 6]. Previous reports have shown that CLIMP-63 plays an important role to maintain endoplasmic reticulum structure [6-9]. Recent studies have shown that CLIMP-63 is closely related to the tumor growth, proliferation, invasion, and metastasis. It has been shown CLIMP-63 could inhibit the proliferation of bladder cancer cells by combining its ligand antiproliferative factor (APF) [10]. Our group reported that the expression of CLIMP-63 was significantly associated with tumor size, lymph node metastasis, and UICC and TNM stage features and was a prognostic marker in patients with intrahepatic cholangiocellular carcinoma (ICC) [11]. In addition, we also reported that CLIMP-63 could inhibit tumor intrahepatic metastasis and venous invasion, and was a prognostic marker in patients with HCC [12]. A study defined CLIMP-63 as a novel protein interactor and regulator of Dicer function, and it can be secreted by cultured human cells with Dicer [13]. Based on the biology role and previous studies of CLIMP-63 in tumors, we aimed to evaluate whether serum CLIMP-63 can be used as a serum biomarker in detection of HCC in this study.

Patients and methods

Patients and samples

Serum samples were obtained before any treatment from 90 patients with HCC who underwent surgery from January 2013 to September 2013 at the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University in Shanghai, China. The blood samples were centrifuged at 3,000 rpm for 15 minutes and stored at -80°C until further assayed. The serum samples of 40 healthy people were obtained from the Health Check Center of Eastern Hepatobiliary Surgery Hospital from July 2013 to September 2013. This research was approved by the Institutional Review Board of the Second Military Medical University and all participants gave written informed consent.

Animals and experimental procedures

DEN was purchased from Wako Pure Chemical Co., Ltd. (Kyoto, Japan) and diluted with a 0.9% NaCl solution to a concentration of 0.1%. Male Sprague-Dawley rats (10 weeks old, average body weight 98.7 ± 6.3 g) were provided by Animal center of The Second Military Medical University. Rats were randomly divided into two groups according to treating with or without DEN (given diethylnitrosamine 25 mg/kg/d by intraperitoneal injection) once a week for 20 weeks. The experiment was terminated at the end of 20 weeks. Rats were sacrificed under light ether anesthesia on weeks 0, 6, 8, 10, 12, 14, 16, 18, 20. Blood samples were taken from via cardiac puncture before sacrifice. The blood samples were centrifuged at 3,000 rpm for 15 min, serum was then separated and kept at -80°C until used for assays. Livers were immediately excised and processed for histological examination.

ELISA agents

CLIMP-63 monoclonal and polyclonal antibodies were purchased from Lifespan and Sigma. Horseradish peroxidase (HRP) labeled antimouse secondary antibody was from Pik days biotechnology Research Institute. TMB reagent was from sigma. Coating solution: Na₂CO₃-NaHCO₃ buffer (PH 9.6). Washing solution: PBS (PH 7.2) plus 0.05% tween-20. Blocking solution: 1% of BSA was added PBS containing 0.1% tween-20. Antibody dilution: PH 7.2 of PBS plus 0.1% BSA. Stop solution: H₂SO₄ (concentration: 2 mol/L). ELISA method was described before [14].

Coimmunoprecipitation assays

Serum samples were prepared in radioimmunoprecipitation assay (RIPA) buffer and incubated with anti-CLIMP-63 antibody (sigma) for 8 h at 4°C, followed by addition of Protein A/G Plus-Agarose (Santa Cruz Biotechnology) for another 4 h. The samples from these assays were centrifuged at 12,000 g for 15 min. Immunoblotting was performed using anti-CLIMP-63 antibody, and immune-complexes were incubated with the fluorescein-conjugated secondary antibody and then detected using Odyssey fluorescence scanner (Li-Cor, Lincoln, NE).
Immunohistochemistry

The tissue sections were dewaxed, rehydrated and then immersed in methanol containing 0.3% hydrogen peroxide (Sinopharm Chemical Reagent Co., Ltd., 10011218) for 30 min to block endogenous peroxidase activity. Pressure cooker filled with 10 mM ethylenediaminetetra acetic buffer (EDTA, pH 8.0) boil heated for 2 min. After blocking, the sections were incubated in a primary polyclonal antibodies against CLIMP-63 (Sigma, HPA000792) with 1:100 dilution. Finally, the visualization signal was developed with diaminobenzidine and the slides were counterstained in hematoxylin. Stained sections were evaluated in a blinded manner without prior knowledge of the clinical information using the German immunoreactive score (IRS). Briefly, the IRS assigns sub-scores for immunoreactive distribution (0-4) and intensity (0-3). The percent positivity was scored as “0” (<5%), “1” (5-25%), “2” (25-50%), “3” (50-75%) or “4” (>75%). The staining intensity was scored as “0” (no staining), “1” (weakly stained), “2” (moderately stained) or “3” (strongly stained).

Figure 1. Liver tissue and serum level of CLIMP-63 on DEN-induced hepatocarcinogenesis in rats. A, B. Immunochemical staining CLIMP-63 expression in DEN induced hepatocarcinogenesis tissues of rats and the immunoreactive score of the protein in specimens. C. Serum CLIMP-63 in DEN-induced HCC was detected by coimmunoprecipitation assays in rats sera of DEN-injection 16 weeks and 6 weeks. D. Serum CLIMP-63 was examined in rats with 0-20 weeks DEN treatment by ELISA. *Indicates P<0.05, **indicates P<0.01.
CLIMP-63 as a serum biomarker for HCC

Statistical analysis

To compare the concentrations of CLIMP-63 and AFP in HCC samples and controls, we calculated P-values for ELISA results by an independent-samples t-test. We constructed receiver operating characteristic (ROC) curves for serum CLIMP-63 and AFP, to assess their diagnostic accuracy in distinguishing HCC patients from normal control subjects. Using the ROC method, we calculated the sensitivity, specificity, and area under the receiver operating characteristic curve (AuROC) to determine the diagnostic accuracy of our findings. Statistical Package for Social Sciences software (SPSS, Inc., Chicago, IL, USA version 17.0) was used for data support and analysis and p values <0.05 were considered as statistically significant differences.

Results

Liver tissue and serum level of CLIMP-63 on DEN-induced hepatocarcinogenesis in rats

Immuohistochemical studies indicated that CLIMP-63 were significantly higher after DEN-injection 6-8 weeks compared with control (Figure 1A, 1B). For analysis the serum concentrations of CLIMP-63 in DEN-induced HCC, we performed coimmunoprecipitation assays in sera from HCC patients and normal persons. Endogenous CLIMP-63 was immunoprecipitated by CLIMP-63 antibody and CLIMP-63 protein, which were determined by western blot assay (Figure 1C). The results showed that CLIMP-63 could be detected in serum of HCC rats. The serum CLIMP-63 was verified by enzyme-linked immunosorbent assays (ELISA) (Figure 1D). The CLIMP-63 levels tended to increase according to the progression of DEN-induced hepatocarcinogenesis in rats. The serum CLIMP-63 level after DEN-bearing 10 weeks was remarkably high than that of non DEN-bearing rats (P<0.05, Figure 1D).

Serum level of CLIMP-63 in human specimen

We performed coimmunoprecipitation assays in serum from HCC patients and normal persons. The results showed that CLIMP-63 could be detected in serum of HCC patients (Figure 2A). Further analysis by ELISA revealed that the CLIMP-63 serum level was obviously higher in
CLIMP-63 as a serum biomarker for HCC

HCC blood samples than it in normal ones (P<0.05, Figure 2B). We also detected the levels of serum CLIMP-63 in normal persons, hepatitis, cirrhosis and HCC patients (Figure 2C). The results show that the CLIMP-63 level tends to increase according to the progression of hepatocarcinogenesis.

**Compare diagnostic accuracy of serum CLIMP-63 and AFP for HCC**

The ROC curve of CLIMP-63 was close to AFP curve, which indicated that CLIMP-63 had comparable diagnosis accuracy to AFP for HCC in our study cohort (Figure 3A). The sensitivity, specificity and AuROC (95% CI) of serum CLIMP-63 for the diagnosis of HCC were 70%, 67.5%, 0.771 (0.678-0.863), respectively. For AFP, the sensitivity, specificity and AuROC (95% CI) were 75.6%, 87.5%, 0.892 (0.838-0.945), respectively (Figure 3A; Table 1). When the AFP concentration ≤20 ng/ml, the sensitivity, specificity and AuROC (95% CI) of serum CLIMP-63 for the diagnosis of HCC were 69.7%, 67.5%, 0.759 (0.651-0.868), respectively. While, for AFP, they

---

**Figure 3.** Comparing diagnostic accuracy of serum CLIMP-63 and AFP for HCC. A. ROC curve for CLIMP-63 or AFP for all patients with HCC versus all controls in the test cohort. The blue line indicates the CLIMP-63 and the green line indicates the AFP. B-D. ROC curves showed the performance of the CLIMP-63 in patients with AFP levels between 20 to 5 ng per milliliter from a total of 130 samples (90 from patients with HCC and 40 from controls).
CLIMP-63 as a serum biomarker for HCC

Table 1. Comparison of AUC, Sensitivity, and Specificity between serum AFP and CLIMP-63 levels for the screening of HCC according to the different AFP Cut-off Values

<table>
<thead>
<tr>
<th>AFP cut-off values (ng/ml)</th>
<th>AUC (CI, 95%) (AFP vs CLIMP-63)</th>
<th>P (AFP vs CLIMP-63)</th>
<th>Sensitivity (%) (AFP vs CLIMP-63)</th>
<th>Specificity (%) (AFP vs CLIMP-63)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;20</td>
<td>0.892 (0.838-0.945) vs 0.771 (0.678-0.863)</td>
<td>0.000 vs 0.000</td>
<td>75.6 vs 70.0</td>
<td>87.5 vs 67.5</td>
</tr>
<tr>
<td>&lt;20</td>
<td>0.705 (0.583-0.826) vs 0.759 (0.651-0.868)</td>
<td>0.003 vs 0.000</td>
<td>63.6 vs 69.7</td>
<td>65.0 vs 67.5</td>
</tr>
<tr>
<td>&lt;10</td>
<td>0.652 (0.517-0.786) vs 0.769 (0.658-0.879)</td>
<td>0.034 vs 0.000</td>
<td>60.7 vs 71.4</td>
<td>60.0 vs 67.5</td>
</tr>
<tr>
<td>&lt;5</td>
<td>0.629 (0.474-0.783) vs 0.777 (0.655-0.898)</td>
<td>0.110 vs 0.000</td>
<td>66.7 vs 76.2</td>
<td>60.0 vs 65.7</td>
</tr>
</tbody>
</table>

Discussion

Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world [15]. Prognosis for this disease is poor since HCC can be mostly only diagnosed at an advantaged stage. Over the past few decades, it has drawn attention worldwide to screen for an early diagnosis of HCC. In order to conveniently detect tumors at an early stage, serum biomarkers play important roles in HCC diagnosis. However, the limitation of AFP from the low sensitivity as the major serum marker for diagnosis of HCC in clinical practice, reliable and novel markers is urgently needed to improve the diagnostic accuracy for HCC. Our recent work indicates that CLIMP-63 is a prognostic marker for intrahepatic cholangiocellular carcinoma and HCC patients and clinicopathologically associated with tumor progression and metastasis [11, 12], making CLIMP-63 an attractive target as a tumor biomarker. To date, the serological diagnosis value of CLIMP-63 for HCC has not been reported.

In this study, for the first time, we evaluated the validity of CLIMP-63 as a serological biomarker for HCC and demonstrated that serum CLIMP-63 levels are sequentially increased in HCC according to progression of disease based on the theory of hepatocarcinogenesis (hepatitis-cirrhosis-carcinoma sequence). Serum CLIMP-63 levels were significantly increased in patients with HCC, compared to those of patients without cancer. The finding in this study may provide a potential marker of CLIMP-63 in diagnosing HCC. The sensitivity of the assay is 70% and the specificity 67.5%, which is similar to AFP with the cutoff value of 20 ng/ml in HCC detection. While, when the AFP cut-off value less than 20 ng/ml, the sensitivity and specificity of CLIMP-63 are much better than AFP in HCC detection. The data presented here indicated that examination of serum CLIMP-63 can increase the diagnostic efficacy when APF is low or negative in HCC patients.

To our knowledge, this is the first report demonstrating higher serum CLIMP-63 levels in HCC patients and the serum CLIMP-63 could improve diagnostic accuracy of HCC as a supplement for AFP. The previous studies indicated that CLIMP-63 located in the endoplasmic reticulum, which evoked a question why CLIMP-63 could be detected in serum. Genevieve and coworkers reported that Dicer transits through the ER and can be secreted by cultured human cells with CLIMP-63 [13]. But the mechanism by which CLIMP-63 was secreted need to be further investigated.

Our study also found that serum CLIMP-63 was elevated when disease was in the stage of hepatitis and cirrhosis compared to normal in human and rat model. The data shown here revealed that detecting the serum level of CLIMP-63 could evaluate the disease sequence of hepatitis-cirrhosis-HCC, and provide evi-
CLIMP-63 as a serum biomarker for HCC

dence for early intervention treatment. However, in this study, there was the relatively small sample size and clinical data collection was not comprehensive, especially for patients with hepatitis and cirrhosis. Further studies with larger sample size from different stage of HCC will be performed to confirm and validate whether CLIMP-63 can be used as a diagnostic marker in hepatitis and cirrhosis.

Acknowledgements

The authors thank their respective laboratory members and collaborators for critical review of this article. This work was supported in part by research grants from the National Natural Science Foundation of China (81370066, 81372355), Shanghai Municipal Health Bureau project (20134444) and the major program of the Natural Science Research of Educational Department Anhui Province (No. KJ2015ZD31).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Zhengrong Zhong, Department of The Clinical Laboratory, The First Affiliated Hospital of Bengbu Medical College, 287 Changhuai Road, Bengbu 233004, Anhui, P. R. China. E-mail: youamonkeyking@yeah.net; Ning Yang, Department of Liver Medicine, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, 225 Changhai Road, Shanghai 200438, P. R. China. E-mail: lancet00@163.com

References